Ambu stock gains acquisition catalyst with TIMS Medical deal

Published on 09/15/2026 at 10:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ambu stock is in focus after the company agreed on September 14, 2026 to acquire US-based TIMS Medical for up to USD 65 million, underscoring its imaging growth strategy. The outlook for fiscal 2025/2026 remains unchanged, giving investors a clearer view on earnings visibility.

Fotorealistische Medizintechnik-Fertigung von Einweg-Endoskopen im Reinraum — Ambu A/S (DK0060946788) zeigt fotorealistisch moderne Medizintechnik-Fertigung von Einweg-Endoskopen in steriler Reinraumumgebung, Illustration mit AI erstellt.

Ambu A/S stock (ISIN DK0060946788) is drawing attention after the Danish medical device company agreed on September 14, 2026 to acquire US-based TIMS Medical for up to USD 65 million, strengthening its position in imaging solutions.

Acquisition of TIMS Medical strengthens imaging portfolio

According to MarketScreener on September 14, 2026, Ambu will acquire TIMS Medical for USD 45 million in cash at closing, plus potential earn-outs of up to USD 20 million based on future performance.

The acquisition expands Ambu's portfolio in imaging and recording solutions for hospitals and health systems, offering a strategic complement to its single-use endoscopy business, and the company confirmed that its outlook for fiscal year 2025/2026 remains unchanged following the deal, according to MarketScreener.

Outlook and earnings visibility for 2025/2026

By reiterating its outlook for fiscal 2025/2026 alongside the acquisition announcement, Ambu signals that the TIMS Medical transaction is intended to be earnings-accretive without requiring changes to its existing guidance framework, as noted by MarketScreener.

For investors, the deal size of up to USD 65 million is moderate compared with typical mid-cap healthcare M&A, which helps Ambu maintain balance sheet flexibility while adding a specialist platform that can drive incremental revenue growth in the imaging segment over the coming fiscal years.

Ambu stock and investor perspective

The combination of a clearly quantified acquisition price and an unchanged outlook for fiscal 2025/2026 gives Ambu stock a defined fundamental narrative as of September 15, 2026, with the TIMS Medical platform expected to contribute to imaging-related revenues once integrated into Ambu's commercial network.